FDA panelists want suicidal-thought warning on ADHD drug

Several members of an FDA advisory panel asked the agency to change the labeling on Novartis' ($NVS) ADHD drug Focalin to reflect a risk of suicidal thoughts. An agency official pointed out, however, that only 8 reports about suicidal ideation have been filed during the 6 years since the drug was approved. Report